PI3K-Akt pathway: its functions and alterations in human cancer
M Osaki, M Oshimura, H Ito - Apoptosis, 2004 - Springer
Abstract Phosphatidylinositol-3-kinase (PI3K) is a lipid kinase and generates
phosphatidylinositol-3, 4, 5-trisphosphate (PI (3, 4, 5) P3). PI (3, 4, 5) P3 is a second …
phosphatidylinositol-3, 4, 5-trisphosphate (PI (3, 4, 5) P3). PI (3, 4, 5) P3 is a second …
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
M Deininger, E Buchdunger, BJ Druker - Blood, 2005 - ashpublications.org
Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …
studies were promising but the results of clinical trials by far exceeded expectations …
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg, PW Manley, W Breitenstein, J Brüggen… - Cancer cell, 2005 - cell.com
Summary The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia
(CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) …
(CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) …
Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations
J LoPiccolo, GM Blumenthal, WB Bernstein… - Drug Resistance …, 2008 - Elsevier
The PI3K/Akt/mTOR pathway is a prototypic survival pathway that is constitutively activated
in many types of cancer. Mechanisms for pathway activation include loss of tumor …
in many types of cancer. Mechanisms for pathway activation include loss of tumor …
Natural course and biology of CML
B Chereda, JV Melo - Annals of hematology, 2015 - Springer
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …
The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA,“ecstasy”)
AR Green, AO Mechan, JM Elliott, E O'Shea… - Pharmacological …, 2003 - ASPET
The amphetamine derivative (±)-3, 4-methylenedioxymethamphetamine (MDMA, ecstasy) is
a popular recreational drug among young people, particularly those involved in the dance …
a popular recreational drug among young people, particularly those involved in the dance …
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
KA West, SS Castillo, PA Dennis - Drug resistance updates, 2002 - Elsevier
The resistance of many types of cancer to conventional chemotherapies is a major factor
undermining successful cancer treatment. In this review, the role of a signal transduction …
undermining successful cancer treatment. In this review, the role of a signal transduction …
Specific targeted therapy of chronic myelogenous leukemia with imatinib
MWN Deininger, BJ Druker - Pharmacological reviews, 2003 - ASPET
Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that
fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9 …
fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9 …
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
FJ Adrián, Q Ding, T Sim, A Velentza, C Sloan… - Nature chemical …, 2006 - nature.com
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder characterized at the
molecular level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated …
molecular level by the expression of Bcr-abl, a 210-kDa fusion protein with deregulated …
The BCR-ABL story: bench to bedside and back
S Wong, ON Witte - Annu. Rev. Immunol., 2004 - annualreviews.org
The twenty-first century is beginning with a sharp turn in the field of cancer therapy.
Molecular targeted therapies against specific oncogenic events are now possible. The BCR …
Molecular targeted therapies against specific oncogenic events are now possible. The BCR …